Selvas Healthcare
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Selvas Healthcare makes two types of products: medical diagnostic devices, including body-composition analysers that measure muscle, fat, and water by passing a small electrical current through the body, and fully automatic blood-pressure monitors, and assistive-technology devices for people with visual impairments, such as braille notetakers and screen-magnification readers.
Its diagnostic devices are used in healthcare and fitness settings, while its assistive devices serve blind and low-vision users. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company operates two distinct product divisions under the brands ACCUNIQ and HIMS.
Summary is AI-generated and may contain errors · figures from DART filings
The company supports its international reach through dedicated subsidiaries in the United States and China, alongside domestic and overseas distributor networks.
Selvas Healthcare in five facts
What does Selvas Healthcare do?
Selvas Healthcare makes two types of products: medical diagnostic devices, including body-composition analysers that measure muscle, fat, and water by passing a small electrical current through the body, and fully automatic blood-pressure monitors, and assistive-technology devices for people with visual impairments, such as braille notetakers and screen-magnification readers.
Where is Selvas Healthcare listed and in which sector?
Selvas Healthcare (Korean name: 셀바스헬스케어) trades under KRX code 208370 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is Selvas Healthcare?
Its market capitalisation was US$46.8M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Selvas Healthcare's latest annual revenue and operating profit?
For fiscal year 2025, Selvas Healthcare reported revenue of US$23.3M, an operating loss of US$121.9K and net income of US$2.9M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 2.8% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Half-year report (2026.06)Sep 30
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Selvas Healthcare reported consolidated results for FY2025: revenue of US$21.4M (−2.8% year on year), an operating loss of US$112K (from a profit a year earlier) and net income of US$2.61M (+19.1% year on year).
Earnings · Feb 19